文献速递肝病

对标准治疗失败自身免疫性肝炎患者,吗替麦考酚酯有益应答可由年龄较大及较低免疫球蛋白G和INR水平预测

Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels.
PubMed 文献 · Aliment Pharmacol Ther · 2019-04-11

这项回顾性观察性队列研究纳入澳大利亚17家肝病中心105例对糖皮质激素联用或不联用硫嘌呤类药物应答不佳或不耐受后接受吗替麦考酚酯挽救治疗的自身免疫性肝炎患者,63例(60%)达到生化缓解;多因素分析显示较低治疗前血清IgG水平、开始吗替麦考酚酯时年龄较高和较高INR是仅有的显著独立预测因素。

要点

  • 105例自身免疫性肝炎患者接受吗替麦考酚酯挽救治疗,63例(60%)达到生化缓解。
  • 多因素分析中较低治疗前IgG、较高年龄和较高INR为独立预测因素。
  • IgG<17 g/L对应答的阳性预测值71%、阴性预测值60%;年龄≥54岁阳性预测值80%、阴性预测值59%。

核心结论

  • 吗替麦考酚酯仍是对标准治疗难治或不耐受的自身免疫性肝炎患者的优良治疗选择,最可能获益者为年龄较大和/或治疗前IgG水平较低者。

研究设计与样本

  • 回顾性观察性队列研究,纳入澳大利亚17家主要肝病中心管理的自身免疫性肝炎患者105例,均为对糖皮质激素联用或不联用硫嘌呤类药物应答不佳或不耐受后接受吗替麦考酚酯者。

主要发现

  • 105例接受吗替麦考酚酯挽救治疗的患者中63例(60%)达到生化缓解。
  • 单因素分析中,年龄较大(P=0.003)、INR<1.1(P=0.02)和较低免疫球蛋白γ(IgG;P<0.002)水平与治疗应答相关,肝硬化状态(P=0.07)和治疗指征(P=0.63)无关联。
  • 多因素分析中,较低治疗前血清IgG水平(P=0.01)、开始吗替麦考酚酯时年龄较高(P=0.01)和较高INR(P=0.03)是仅有的显著独立预测因素。
  • IgG水平<17 g/L对治疗应答的阳性预测值为71%、阴性预测值为60%;开始吗替麦考酚酯时年龄≥54岁对治疗应答的阳性预测值为80%、阴性预测值为59%。

关键数值与推荐

  • IgG水平<17 g/L对治疗应答的阳性预测值71%、阴性预测值60%。
  • 开始吗替麦考酚酯时年龄≥54岁对治疗应答的阳性预测值80%、阴性预测值59%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mycophenolate mofetil is a commonly used salvage therapy for patients with autoimmune hepatitis (AIH). AIM: To evaluate the predictors of response to mycophenolate rescue therapy to facilitate clinical decision making. METHODS: We performed a retrospective observational cohort study of AIH patients managed in 17 major Australian liver centres who received mycophenolate after an inadequate response or intolerance to corticosteroids with/without thiopurine(s). Baseline demographic, clinical and laboratory variables were compared between responders and nonresponders. A multivariable logistic regression model was developed using forward selection to identify independent predictors of treatment response. RESULTS: A total of 105 patients received mycophenolate rescue therapy of whom 63 (60%) achieved biochemical remission. On univariable analysis, older age (P = 0.003), INR < 1.1 (P = 0.02), and lower immunoglobulin gamma (IgG; P < 0.002) levels were associated with treatment response, while no association was found with cirrhosis status (P = 0.07) or treatment indication (P = 0.63). On multivariable analysis, lower pre-treatment serum IgG level (P = 0.01), higher age at commencing mycophenolate (P = 0.01) and higher INR (P = 0.03) were the only significant independent predictors. An IgG level <17 g/L had a positive and negative predictive value for response of 71% and 60% respectively, while age ≥54 years when commencing mycophenolate had a positive and negative predictive value for response of 80% and 59% respectively. CONCLUSION: Mycophenolate remains an excellent treatment option for patients with AIH refractory to or intolerant of standard therapy with those most likely to benefit being older and/or having lower pre-treatment IgG levels.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Nicoll AJ, Roberts SK, Lim R, et al. Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels. Aliment Pharmacol Ther. 2019. PMID: 30972807. doi:10.1111/apt.15248

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。